Skip to main content
. 2010 Jun 24;10:188. doi: 10.1186/1471-2334-10-188

Figure 2.

Figure 2

Probability of occurrence of grade III/IV rash or hepatotoxicity during the three months of follow-up in women initiating a nevirapine-based antiretroviral therapy according to the period of the initiation of treatment (pregnant and non pregnant women) . MTCT-Plus program in Abidjan, Côte d'Ivoire